The Illusion of High Yields in Chemical Dividends
Chemical stocks are flashing some of the highest dividend yields in the sector, but the gap between screener numbers and actual payouts hides a story investors have not noticed yet. Trailing yield calculations can be distorted when companies cut dividends partway through the year, as the window still holds old, larger checks while the rate being paid is lower. This mechanical lag creates a misleading picture of income potential for retail investors scanning financial data feeds.
All but one of seven major U.S.-listed chemical names have reduced their quarterly payouts. The sector-wide correction, completed inside roughly two years, has left only LyondellBasell as the sole holdout among the group analyzed by 247WallSt. Celanese, Chemours, Huntsman, and Dow have all participated in this contraction, with Celanese reducing its common dividend from $0.70 to $0.03, marking the most severe reduction of the group.
LyondellBasell’s Trailing Yield Trap
LyondellBasell (NYSE:LYB) shows a dividend yield of 7.09% on one widely used data feed despite having cut its dividend. The company paid $1.37 per share each quarter before its reduction, with the first ex-dividend date at the new $0.69 rate occurring on March 2, 2026. LyondellBasell’s trailing 12-month total reads $3.44 because it combines both rates, while its annualized forward rate is $2.76.
LyondellBasell shares sit at $57.92, up 38.2% year to date. Despite the stock price appreciation, the underlying earnings coverage remains problematic. LyondellBasell’s trailing diluted EPS is -$0.83, meaning GAAP earnings do not cover the payout.
Cash flow dynamics have been volatile for the company. In the June quarter, LyondellBasell’s operating cash flow of $752 million topped capital spending of $270 million and dividends of $224 million. However, in the March quarter, LyondellBasell’s operating cash flow was negative $269 million against a $224 million dividend bill.
LyondellBasell management tied strong quarterly performance to Middle East supply disruption. CFO Agustin Izquierdo stated on the July call that “investment grade continues to be paramount,” with the near-term priority to “rebuild the balance sheet.” CEO Peter Vanacker said normalization will be “measured in quarters, not months,” which could stretch the margin boost.
FMC’s Deep Discount and Structural Challenges
FMC (NYSE:FMC) paid $0.58 a quarter before cutting to $0.08, with the first ex-dividend date at the lower rate on December 31, 2025. FMC’s trailing 12-month total is $0.82, while its annualized forward rate is $0.32. FMC produces a screener yield of 8.56% with the stock trading at $9.30.
FMC shares are down 71.39% over the past year. The company’s financial health reflects significant headwinds. FMC’s trailing diluted EPS is -$21.49, and the second quarter produced a GAAP net loss of $186.6 million, including $222.3 million of restructuring.
FMC’s full-year adjusted EPS guidance stands at $1.19 to $1.49. FMC’s free cash flow guidance of $75 million to $225 million includes a one-time $200 million licensing payment from Corteva. The company’s balance sheet remains leveraged; FMC’s net debt ran 5.1 times trailing EBITDA at quarter-end, with deleveraging leaning on asset sales plus an equity investment from Tessenderlo that has since closed.
FMC management’s outlook rests on a return to growth in 2027. This timeline suggests that the current low dividend rate is intended to preserve capital during a prolonged period of financial restructuring rather than reflecting immediate operational recovery.
Sector-Wide Dividend Contraction
The broader chemical sector has seen uniform reductions across its largest players. Celanese (NYSE:CE), Chemours (NYSE:CC), Huntsman (NYSE:HUN) and Dow (NYSE:DOW) round out a sector-wide correction completed inside roughly two years.
Chemours reduced its quarterly dividend from $0.25 to $0.0875. Huntsman reduced its quarterly dividend from $0.25 to $0.0875. Dow reduced its quarterly dividend from $0.70 to $0.35.
These cuts illustrate a fundamental shift in capital allocation priorities within the industry. As margins compress and growth slows, companies are prioritizing balance sheet repair over shareholder returns. The high yields visible on screening tools are artifacts of past payouts that no longer reflect current corporate strategy or financial reality.